semaglutide chronic kidney disease stage 3 dosing in Diabetic Disease: Integrating Clinical Evidence with Mechanistic Insights Effects of Semaglutide on Albuminuria

[DOI] [PubMed] [Google Scholar] 67.Severin S.E., Kirzon M.V., Kaftanova T.M

Key points The weight loss induced by glucagon-like peptide receptor 1 agonists (GLP1RAs) should reduce the risk of some malignancies, although stimulation of GLP1 receptors might have either detrimental or beneficial direct effects on cancer risk

Ingredients Ingredients: Liposome mixture [maltodextrin (potato), sunflower lecithin], L-glutathione (reduced), capsule shell (filler: hydroxypropyl methylcellulose)

Wegovy commonly causes nausea, vomiting, and gastrointestinal discomfort, particularly when initiating treatment or increasing doses